Details of the Drug

General Information of Drug (ID: DMMQ8ZG)

Drug Name
Furosemide
Synonyms
Aisemide; Aldalix; Aldic; Aluzine; Anfuramaide; Aquarid; Aquasin; Arasemide; Beronald; Bioretic; Cetasix; Depix; Desal; Desdemin; Dirine; Disal; Discoid; Disemide; Diural; Diurapid; Diurin; Diurolasa; Diusemide; Diusil; Diuzol; Dranex; Dryptal; Durafurid; Edemid; Edenol; Eliur; Endural; Errolon; Eutensin; FUN; Farsix; Fluidrol; Fluss; Franyl; Frumex; Frumide; Frusedan; Frusema; Frusemid; Frusemide; Frusemin; Frusenex; Frusetic; Frusid; Fulsix; Fuluvamide; Fuluvamine; Fulvamide; Furanthril; Furanthryl; Furantral; Furantril; Furanturil; Furesis; Furetic; Furex; Furfan; Furix; Furmid; Furobeta; Furocot; Furodiurol; Furodrix; Furomen; Furomex; Furorese; Furosan; Furose; Furosedon; Furosemid; Furosemida; Furosemidu; Furosemidum; Furosemix; Furoside; Furosifar; Furosix; Furoter; Furovite; Fursemid; Fursemida; Fursemide; Fursol; Fusid; Golan; Hissuflux; Hydrex; Hydro; Hydroled; Impugan; Jenafusid; Katlex; Kofuzon; Kolkin; Kutrix; Lasemid; Lasex; Lasiletten; Lasilix; Lasix; Laxur; Lazix; Liside; Logirene; Lowpston; Lowpstron; Luscek; Macasirool; Marsemide; Mirfat; Mita; Moilarorin; Myrosemide; Nadis; Nelsix; Novosemide; Odemase; Odemex; Oedemex; Prefemin; Profemin; Promedes; Promide; Protargen; Puresis; Radisemide; Radonna; Radouna; Retep; Rosemide; Rosis; Rusyde; Salinex; Salix; Salurex; Salurid; Seguril; Selectofur; Sigasalur; Spirofur; Synephron; Transit; Trofurit; Uremide; Uresix; Urian; Uridon; Uritol; Urosemide; Vesix; Yidoli; Zafimida; FUROSEMIDE USP; Fu sid; Furosemide Monohydrochloride; Furosemide Monosodium Salt; Furosemidu [Polish]; Lasix Retard; Lasix Special; Less Diur; Polysquall A; Sal diureticum; F0182; F4381_SIGMA; LB 502; Aisemide (TN); Apo-Frusemide; Apo-Furosemide; Beronald (TN); Desdemin (TN); Discoid (TN); Diumide-K; Diural (TN); Diurapid (TN); Dryptal (TN); Durafurid (TN); Errolon (TN); Eutensin (TN); Frudix (TN); Frusetic (TN); Frusid (TN); Fulsix (TN); Fuluvamide (TN); Furesis (TN); Furix (TN); Furo-Basan; Furo-puren; Furomide M.D; Furosedon (TN); Furosemida [INN-Spanish]; Furosemide (mita); Furosemidum [INN-Latin]; Hoe-058A; Hydro-rapid; Impugan (TN); Katlex (TN); LB-502; Lasilix (TN); Lasix (TN); Lodix (TN); Lowpston (TN); Macasirool (TN); Mirfat (TN); Neo-renal; Nicorol (TN); Odemase (TN); Oedemex (TN); Profemin (TN); Rosemide (TN); Rusyde (TN); Salix (TN); Salix (brand of furosemide); Trofurit (TN); Urex (TN); Urex-M; Apo-Furosemide (TN); Furo-Puren (TN); Furomide M.D.; Furosemide [USAN:INN:JAN]; Hydro-rapid(TN); Lasix, Frusemide, Furosemide; Furosemide (JP15/USP/INN); Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure; Chlor-N-(2-furylmethyl)-5-sulfamylanthranilsaeure [German]; 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid; 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid; 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid; 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid; 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid; 4-chloro-2-[(furan-2-ylmethyl)amino]-5-sulfamoylbenzoic acid
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1], [2]
Therapeutic Class
Diuretics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 330.74
Topological Polar Surface Area (xlogp) 2
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [4]
Bioavailability
The bioavailability of drug is 60-82% [3]
Clearance
The clearance of drug is 1.23 mL/min/kg [5]
Elimination
The kidneys are responsible for 85% of total furosemide total clearance, where about 43% of the drug undergoes renal excretion [6]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 hours (40 mg furosemide oral adminutesistration) [7]
Metabolism
The drug is metabolized via the kidney [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 25.91513 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.012% [9]
Vd
The volume of distribution (Vd) of drug is 0.181 L/kg [5]
Chemical Identifiers
Formula
C12H11ClN2O5S
IUPAC Name
4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid
Canonical SMILES
C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
InChI
InChI=1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)
InChIKey
ZZUFCTLCJUWOSV-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3440
ChEBI ID
CHEBI:47426
CAS Number
54-31-9
DrugBank ID
DB00695
TTD ID
D0PQ3G
VARIDT ID
DR00258
INTEDE ID
DR0757
ACDINA ID
D00295

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Solute carrier family 12 member 1 (SLC12A1) TTS087L S12A1_HUMAN Blocker [10]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [11]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [12]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Furosemide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Chlorothiazide DMLHESP Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Chlorothiazide. Heart failure [BD10-BD1Z] [64]
Hydroflumethiazide DMVPUQI Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Hydroflumethiazide. Heart failure [BD10-BD1Z] [64]
Digitoxin DMWVIGP Moderate Increased risk of hypokalemia by the combination of Furosemide and Digitoxin. Heart failure [BD10-BD1Z] [65]
Coadministration of a Drug Treating the Disease Different from Furosemide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cefuroxime DMSIMD8 Moderate Increased renal excretion of Furosemide caused by Cefuroxime. Acute bronchitis [CA42] [66]
Framycetin DMF8DNE Major Increased risk of ototoxicity by the combination of Furosemide and Framycetin. Alcoholic liver disease [DB94] [67]
Cefamandole DMNEXZF Moderate Increased renal excretion of Furosemide caused by Cefamandole. Anaerobic bacterial infection [1A00-1A09] [66]
Dronedarone DMA8FS5 Major Increased risk of ventricular arrhythmias by the combination of Furosemide and Dronedarone. Angina pectoris [BA40] [68]
Salbutamol DMN9CWF Moderate Increased risk of hypokalemia by the combination of Furosemide and Salbutamol. Asthma [CA23] [69]
Cefotetan DM07TX3 Moderate Increased renal excretion of Furosemide caused by Cefotetan. Bacterial infection [1A00-1C4Z] [66]
Kanamycin DM2DMPO Major Increased risk of nephrotoxicity by the combination of Furosemide and Kanamycin. Bacterial infection [1A00-1C4Z] [67]
Ceftizoxime DM3VOGS Moderate Increased renal excretion of Furosemide caused by Ceftizoxime. Bacterial infection [1A00-1C4Z] [66]
Cefoperazone DM53PV8 Moderate Increased renal excretion of Furosemide caused by Cefoperazone. Bacterial infection [1A00-1C4Z] [66]
Cefprozil DM7DSYP Moderate Increased renal excretion of Furosemide caused by Cefprozil. Bacterial infection [1A00-1C4Z] [66]
Ceftriaxone DMCEW64 Moderate Increased renal excretion of Furosemide caused by Ceftriaxone. Bacterial infection [1A00-1C4Z] [66]
Streptomycin DME1LQN Major Increased risk of nephrotoxicity by the combination of Furosemide and Streptomycin. Bacterial infection [1A00-1C4Z] [67]
Cefepime DMHVWIK Moderate Increased renal excretion of Furosemide caused by Cefepime. Bacterial infection [1A00-1C4Z] [66]
Cefaclor DMJXDGC Moderate Increased renal excretion of Furosemide caused by Cefaclor. Bacterial infection [1A00-1C4Z] [66]
Gentamicin DMKINJO Major Increased risk of ototoxicity by the combination of Furosemide and Gentamicin. Bacterial infection [1A00-1C4Z] [67]
Cefadroxil DMMC345 Moderate Increased renal excretion of Furosemide caused by Cefadroxil. Bacterial infection [1A00-1C4Z] [66]
Rabeprazole DMMZXIW Moderate Increased risk of hypomagnesemia by the combination of Furosemide and Rabeprazole. Bacterial infection [1A00-1C4Z] [70]
Cefazolin DMPDYFR Moderate Increased renal excretion of Furosemide caused by Cefazolin. Bacterial infection [1A00-1C4Z] [66]
Netilmicin DMRD1QK Major Increased risk of ototoxicity by the combination of Furosemide and Netilmicin. Bacterial infection [1A00-1C4Z] [67]
Cefditoren DMSUVM1 Moderate Increased renal excretion of Furosemide caused by Cefditoren. Bacterial infection [1A00-1C4Z] [66]
Cefonicid DMTX2BH Moderate Increased renal excretion of Furosemide caused by Cefonicid. Bacterial infection [1A00-1C4Z] [66]
Cefradine DMUNSWV Moderate Increased renal excretion of Furosemide caused by Cefradine. Bacterial infection [1A00-1C4Z] [66]
Cefoxitin DMYTXVR Moderate Increased renal excretion of Furosemide caused by Cefoxitin. Bacterial infection [1A00-1C4Z] [66]
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Furosemide and Cariprazine. Bipolar disorder [6A60] [71]
Etidronic acid DM1XHYJ Moderate Increased risk of hypocalcemia by the combination of Furosemide and Etidronic acid. Bone paget disease [FB85] [72]
Risedronate DM5FLTY Moderate Increased risk of hypocalcemia by the combination of Furosemide and Risedronate. Bone paget disease [FB85] [72]
Ceftibuten DMWV2AG Moderate Increased renal excretion of Furosemide caused by Ceftibuten. Bronchitis [CA20] [66]
Phenylbutazone DMAYL0T Moderate Antagonize the effect of Furosemide when combined with Phenylbutazone. Chronic pain [MG30] [73]
Ketoprofen DMRKXPT Moderate Antagonize the effect of Furosemide when combined with Ketoprofen. Chronic pain [MG30] [73]
Levomilnacipran DMV26S8 Moderate Increased risk of hyponatremia by the combination of Furosemide and Levomilnacipran. Chronic pain [MG30] [74]
Sertraline DM0FB1J Moderate Increased risk of hyponatremia by the combination of Furosemide and Sertraline. Depression [6A70-6A7Z] [74]
Vilazodone DM4LECQ Moderate Increased risk of hyponatremia by the combination of Furosemide and Vilazodone. Depression [6A70-6A7Z] [74]
Paroxetine DM5PVQE Moderate Increased risk of hyponatremia by the combination of Furosemide and Paroxetine. Depression [6A70-6A7Z] [74]
Selegiline DM6034S Moderate Additive hypotensive effects by the combination of Furosemide and Selegiline. Depression [6A70-6A7Z] [75]
Vortioxetine DM6F1PU Moderate Increased risk of hyponatremia by the combination of Furosemide and Vortioxetine. Depression [6A70-6A7Z] [74]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Furosemide and Isocarboxazid. Depression [6A70-6A7Z] [75]
Milnacipran DMBFE74 Moderate Increased risk of hyponatremia by the combination of Furosemide and Milnacipran. Depression [6A70-6A7Z] [74]
Escitalopram DMFK9HG Moderate Increased risk of hyponatremia by the combination of Furosemide and Escitalopram. Depression [6A70-6A7Z] [74]
Tranylcypromine DMGB5RE Moderate Additive hypotensive effects by the combination of Furosemide and Tranylcypromine. Depression [6A70-6A7Z] [75]
Desvenlafaxine DMHD4PE Moderate Increased risk of hyponatremia by the combination of Furosemide and Desvenlafaxine. Depression [6A70-6A7Z] [74]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Furosemide and OPC-34712. Depression [6A70-6A7Z] [71]
Phenelzine DMHIDUE Moderate Additive hypotensive effects by the combination of Furosemide and Phenelzine. Depression [6A70-6A7Z] [75]
Diazepam DM08E9O Moderate Additive hypotensive effects by the combination of Furosemide and Diazepam. Epilepsy/seizure [8A61-8A6Z] [76]
Eslicarbazepine DMZREFQ Moderate Increased risk of hyponatremia by the combination of Furosemide and Eslicarbazepine. Epilepsy/seizure [8A61-8A6Z] [77]
Ethacrynic acid DM60QMR Major Increased risk of ototoxicity by the combination of Furosemide and Ethacrynic acid. Essential hypertension [BA00] [78]
Nadolol DMW6GVL Moderate Increased risk of hyperglycemia by the combination of Furosemide and Nadolol. Essential hypertension [BA00] [79]
Mefenamic acid DMK7HFI Moderate Antagonize the effect of Furosemide when combined with Mefenamic acid. Female pelvic pain [GA34] [73]
Dexlansoprazole DM1DBV5 Moderate Increased risk of hypomagnesemia by the combination of Furosemide and Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [70]
Metipranolol DMJMVKI Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Metipranolol. Glaucoma [9C61] [79]
Levobetaxolol DMSREPX Moderate Increased risk of hypertriglyceridemia by the combination of Furosemide and Levobetaxolol. Glaucoma [9C61] [79]
Levobunolol DMTNFCQ Moderate Increased risk of hypertriglyceridemia by the combination of Furosemide and Levobunolol. Glaucoma [9C61] [79]
Etelcalcetide DMHP9BL Major Increased risk of hypocalcemia by the combination of Furosemide and Etelcalcetide. Hyper-parathyroidism [5A51] [80]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Furosemide due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [80]
Acebutolol DM0TI4U Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Acebutolol. Hypertension [BA00-BA04] [79]
Captopril DM458UM Moderate Increased risk of hyponatremia by the combination of Furosemide and Captopril. Hypertension [BA00-BA04] [81]
Penbutolol DM4ES8F Moderate Increased risk of hyperglycemia by the combination of Furosemide and Penbutolol. Hypertension [BA00-BA04] [79]
Nebivolol DM7F1PA Moderate Increased risk of hypertriglyceridemia by the combination of Furosemide and Nebivolol. Hypertension [BA00-BA04] [79]
Pindolol DMD2NV7 Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Pindolol. Hypertension [BA00-BA04] [79]
Indapamide DMGN1PW Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Indapamide. Hypertension [BA00-BA04] [64]
Trichlormethiazide DMHAQCO Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Trichlormethiazide. Hypertension [BA00-BA04] [64]
Perindopril DMOPZDT Moderate Additive hypotensive effects by the combination of Furosemide and Perindopril. Hypertension [BA00-BA04] [81]
Quinapril DMR8H31 Moderate Additive hypotensive effects by the combination of Furosemide and Quinapril. Hypertension [BA00-BA04] [81]
Lisinopril DMUOK4C Moderate Additive hypotensive effects by the combination of Furosemide and Lisinopril. Hypertension [BA00-BA04] [81]
Hydrochlorothiazide DMUSZHD Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Hydrochlorothiazide. Hypertension [BA00-BA04] [64]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Furosemide and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [82]
Meclofenamic acid DM05FXR Moderate Antagonize the effect of Furosemide when combined with Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [73]
Propiomazine DMKY8V1 Moderate Additive hypotensive effects by the combination of Furosemide and Propiomazine. Insomnia [7A00-7A0Z] [71]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Furosemide and ITI-007. Insomnia [7A00-7A0Z] [71]
Ibandronate DM0QZBN Moderate Increased risk of hypocalcemia by the combination of Furosemide and Ibandronate. Low bone mass disorder [FB83] [83]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Furosemide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [84]
Ozanimod DMT6AM2 Moderate Additive hypotensive effects by the combination of Furosemide and Ozanimod. Multiple sclerosis [8A40] [75]
Promethazine DM6I5GR Moderate Additive hypotensive effects by the combination of Furosemide and Promethazine. Nausea/vomiting [MD90] [71]
Sibutramine DMFJTDI Moderate Increased risk of hyponatremia by the combination of Furosemide and Sibutramine. Obesity [5B80-5B81] [74]
Polythiazide DMCH80F Moderate Increased risk of fluid/electrolyte loss by the combination of Furosemide and Polythiazide. Oedema [MG29] [64]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Furosemide and Levomethadyl Acetate. Opioid use disorder [6C43] [85]
Naproxen DMZ5RGV Moderate Antagonize the effect of Furosemide when combined with Naproxen. Osteoarthritis [FA00-FA05] [73]
Carboplatin DMG281S Moderate Increased risk of ototoxicity by the combination of Furosemide and Carboplatin. Ovarian cancer [2C73] [82]
Etodolac DM6WJO9 Moderate Antagonize the effect of Furosemide when combined with Etodolac. Pain [MG30-MG3Z] [73]
Diflunisal DM7EN8I Moderate Antagonize the effect of Furosemide when combined with Diflunisal. Pain [MG30-MG3Z] [73]
Ibuprofen DM8VCBE Moderate Antagonize the effect of Furosemide when combined with Ibuprofen. Pain [MG30-MG3Z] [73]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Furosemide and Safinamide. Parkinsonism [8A00] [75]
Rasagiline DM3WKQ4 Moderate Additive hypotensive effects by the combination of Furosemide and Rasagiline. Parkinsonism [8A00] [75]
Esomeprazole DM7BN0X Moderate Increased risk of hypomagnesemia by the combination of Furosemide and Esomeprazole. Peptic ulcer [DA61] [70]
Bromfenac DMKB79O Moderate Antagonize the effect of Furosemide when combined with Bromfenac. Postoperative inflammation [1A00-CA43] [73]
Levomepromazine DMIKFEL Moderate Additive hypotensive effects by the combination of Furosemide and Levomepromazine. Psychotic disorder [6A20-6A25] [71]
Meloxicam DM2AR7L Moderate Antagonize the effect of Furosemide when combined with Meloxicam. Rheumatoid arthritis [FA20] [73]
Oxaprozin DM9UB0P Moderate Antagonize the effect of Furosemide when combined with Oxaprozin. Rheumatoid arthritis [FA20] [73]
Flurbiprofen DMGN4BY Moderate Antagonize the effect of Furosemide when combined with Flurbiprofen. Rheumatoid arthritis [FA20] [73]
Quetiapine DM1N62C Moderate Additive hypotensive effects by the combination of Furosemide and Quetiapine. Schizophrenia [6A20] [71]
Mesoridazine DM2ZGAN Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Mesoridazine. Schizophrenia [6A20] [82]
Aripiprazole DM3NUMH Moderate Additive hypotensive effects by the combination of Furosemide and Aripiprazole. Schizophrenia [6A20] [71]
Iloperidone DM6AUFY Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Iloperidone. Schizophrenia [6A20] [82]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Paliperidone. Schizophrenia [6A20] [82]
Perphenazine DMA4MRX Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Perphenazine. Schizophrenia [6A20] [82]
Molindone DMAH70G Moderate Additive hypotensive effects by the combination of Furosemide and Molindone. Schizophrenia [6A20] [71]
Thiothixene DMDINC4 Moderate Additive hypotensive effects by the combination of Furosemide and Thiothixene. Schizophrenia [6A20] [71]
Trifluoperazine DMKBYWI Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Trifluoperazine. Schizophrenia [6A20] [82]
Risperidone DMN6DXL Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Risperidone. Schizophrenia [6A20] [82]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Furosemide and Amisulpride. Schizophrenia [6A20] [82]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Furosemide and Asenapine. Schizophrenia [6A20] [71]
Pimozide DMW83TP Major Increased risk of ventricular arrhythmias by the combination of Furosemide and Pimozide. Schizophrenia [6A20] [86]
Cephapirin DMV2JNY Moderate Increased renal excretion of Furosemide caused by Cephapirin. Sepsis [1G40-1G41] [66]
Plazomicin DMKMBES Major Increased risk of nephrotoxicity by the combination of Furosemide and Plazomicin. Urinary tract infection [GC08] [67]
Methdilazine DMAUHQX Moderate Additive hypotensive effects by the combination of Furosemide and Methdilazine. Vasomotor/allergic rhinitis [CA08] [71]
Trimeprazine DMEMV9D Moderate Additive hypotensive effects by the combination of Furosemide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [87]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Furosemide and Amiodarone. Ventricular tachyarrhythmia [BC71] [88]
⏷ Show the Full List of 106 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrazine yellow E00409 164825 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Furosemide 12.5 mg tablet 12.5 mg Oral Tablet Oral
Furosemide 20 mg tablet 20 mg Oral Tablet Oral
Furosemide 40 mg tablet 40 mg Oral Tablet Oral
Furosemide 50 mg tablet 50 mg Oral Tablet Oral
Furosemide 80 mg tablet 80 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4839).
2 Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators. Rev Cardiovasc Med. 2008 Winter;9(1):39-45.
3 FDA Approved Drug Products: Retevmo (selpercatinib) capsules
4 BDDCS applied to over 900 drugs
5 Andreasen F, Mikkelsen E: Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol. 1977 Aug 17;12(1):15-22. doi: 10.1007/bf00561400.
6 Nichols DJ, Muirhead GJ, Harness JA: Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1:5S-12S.
7 Furosemide - FDA Label
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
10 Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
11 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
12 Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9.
13 Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1 and 3A2 in furosemide metabolism. J Pharm Pharmacol. 2009 Jan;61(1):47-54.
14 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
15 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
16 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
17 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
18 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
19 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
20 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
21 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
22 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
23 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
24 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
25 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
26 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
27 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
28 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
29 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
30 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
31 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
32 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
33 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
34 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
35 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
36 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
37 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
38 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
39 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
40 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
41 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
42 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
43 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
44 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
45 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
46 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
47 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
48 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
49 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
50 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
51 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
52 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
53 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
54 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
55 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
56 Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
57 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
58 Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
59 Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
60 Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
61 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
62 Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
63 The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.
64 Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61. [PMID: 6701709]
65 Brown DD, Dormois JC, Abraham GN, et al "Effect of furosemide on the renal excretion of digoxin." Clin Pharmacol Ther 20 (1976): 395-400. [PMID: 975715]
66 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
67 Athlin L, Domellof L, Holm S "Gentamicin treatment in severe surgical infections: serum levels, interactions, toxicity and efficacy." Acta Chir Scand 147 (1981): 225-30. [PMID: 7034430]
68 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
69 Lipworth BJ, McDevitt DG, Struthers AD "Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol." Am J Med 86 (1989): 653-7. [PMID: 2729315]
70 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".
71 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
72 Product Information. Skelid (tilundronate). Sanofi Winthrop Pharmaceuticals, New York, NY.
73 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
74 Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
75 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
76 Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
77 Product Information. Aptiom (eslicarbazepine). Sunovion Pharmaceuticals Inc, Marlborough, MA.
78 Arnold W, Nadol JB Jr, Weidauer H "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh) 91 (1981): 399-414. [PMID: 6973908]
79 Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
80 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
81 Burnakis TG, Mioduch HJ "Combined therapy with captopril and potassium supplementation: a potential for hyperkalemia." Arch Intern Med 144 (1984): 2371-2. [PMID: 6391404]
82 Cerner Multum, Inc. "Australian Product Information.".
83 Product Information. Zometa (zoledronic acid). Novartis Pharmaceuticals, East Hanover, NJ.
84 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
85 Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
86 Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
87 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
88 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]